Rite Aid Hit With $5M Fine in Drug Diversion Scheme

PANAMA CITY, FL – Rite Aid is shelling out $5 million to federal prosecutors after a years-long investigation exposed widespread failures in its handling of highly addictive prescription drugs. The feds allege the pharmacy giant knowingly allowed, and in some cases actively participated in, the illegal diversion of powerful narcotics across eight states, contributing to the nation’s raging opioid crisis.

The investigation, initiated in 2004, focused on 53 Rite Aid locations and revealed a disturbing pattern of negligence and outright violations of the Controlled Substances Act (CSA). In Kentucky and New York, Rite Aid pharmacies allegedly filled prescriptions for controlled substances with no legitimate medical basis – essentially rubber-stamping orders from doctors with questionable practices. This allowed dangerous drugs to flow into the hands of abusers, fueling addiction and street sales.

Beyond knowingly filling illicit prescriptions, the feds found Rite Aid consistently failed to report significant thefts and losses of narcotics. At pharmacies in Maryland, New York, and California, missing drugs weren’t reported to the Drug Enforcement Administration (DEA) in a timely manner, allowing the diversion to continue unchecked. In some cases, the company also failed to maintain or provide required records when requested by investigators, obstructing the investigation.

The scope of the problem extended beyond simple negligence. Accountability audits at 25 of the investigated stores revealed significant discrepancies in controlled substance inventories, including shortages of highly abused drugs like oxycodone and hydrocodone. These weren’t minor accounting errors; they were clear indicators that drugs were disappearing without proper explanation, pointing to internal theft or illegal sales. The DEA found surpluses too, suggesting drugs were being improperly accumulated.

As part of the settlement, Rite Aid is required to implement a strict new compliance plan with the DEA, including a nationwide pseudoephedrine and ephedrine tracking system designed to curb methamphetamine production. They’ll also be conducting comprehensive audits of all pharmacies and increasing the frequency of controlled substance counts – going beyond what the CSA currently requires. Quarterly counts of Schedule II drugs and annual counts of hydrocodone and alprazolam are now mandatory.

“Congress regulates these drugs for a reason,” stated Deputy Attorney General Mark Filip. “This settlement is a warning to all pharmacies: you have a responsibility to protect public health and prevent these dangerous substances from falling into the wrong hands.” DEA Acting Administrator Michele Leonhart echoed the sentiment, emphasizing that pharmacies must be proactive in combating drug abuse, not complicit in it. The feds are clearly sending a message: lax security and record-keeping will not be tolerated when lives are at stake.

RELATED: Army Families Ripped Off: $31M Kickback

RELATED: MS-13 Hitmen Get Decades for Maryland Murder